Advertisement
Advertisement
AXSM
Axsome Therapeutics, Inc
178.06
USDSponsored
-0.84
-0.47%
Apr 10, 15:59 UTC -4
Closed
After-Market
178.09
+0.03
+0.02%
AXSM Earnings Reports
Positive Surprise Ratio
AXSM beat 21 of 41 last estimates.
51%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$197.89M
/-$0.84
Implied change from Q4 25 (Revenue/ EPS)
+0.96%
/+50.00%
Implied change from Q1 25 (Revenue/ EPS)
+62.92%
/-31.15%
Axsome Therapeutics, Inc earnings per share and revenue
On Feb 23, 2026, AXSM reported earnings of -0.56 USD per share (EPS) for Q4 25, beating the estimate of -0.68 USD, resulting in a 17.96% surprise. Revenue reached 196.00 million, compared to an expected 196.97 million, with a -0.49% difference. The market reacted with a -1.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.84 USD, with revenue projected to reach 197.89 million USD, implying an increase of 50.00% EPS, and increase of 0.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Axsome Therapeutics, Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Axsome Therapeutics, Inc reported EPS of -$0.56, beating estimates by 17.96%, and revenue of $196.00M, -0.49% below expectations.
How did the market react to Axsome Therapeutics, Inc's Q4 2025 earnings?
The stock price moved down -1.41%, changed from $176.82 before the earnings release to $174.33 the day after.
When is Axsome Therapeutics, Inc expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Axsome Therapeutics, Inc's next earnings report?
Based on 13
analysts, Axsome Therapeutics, Inc is expected to report EPS of -$0.84 and revenue of $197.89M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement